Research Abstract


A novel potent tumour promoter aberrantly overexpressed in most human cancers

2011年6月14日 Scientific Reports 1 : 15 doi: 10.1038/srep00015


高橋 淳1,2,4,時田尚志3*,竹岡友晴4,村山皇翔1,友常 大八郎2,大平美紀2,岩松明彦6,小原一朗7,矢崎一史7,好田忠行8,中川原 章2 & 谷 憲三朗1

  1. 九州大学 生体防御医学研究所 ゲノム病態学分野
  2. 千葉県がんセンター生化学研究部
  3. 千葉県がんセンター研究局 動物管理室
  4. 京都大学大学院医学研究科 血液・腫瘍内科学
  5. 京都大学大学院医学研究科 皮膚生命科学
  6. 有限会社 プロテイン・リサーチ・ネットワーク
  7. 京都大学生存圏研究所 森林圏遺伝子統御分野
  8. 久光製薬 株式会社
The complexity and heterogeneity of tumours have hindered efforts to identify commonalities among different cancers. Furthermore, because we have limited information on the prevalence and nature of ubiquitous molecular events that occur in neoplasms, it is unfeasible to implement molecular-targeted cancer screening and prevention. Here, we found that the FEAT protein is overexpressed in most human cancers, but weakly expressed in normal tissues including the testis, brain, and liver. Transgenic mice that ectopically expressed FEAT in the thymus, spleen, liver, and lung spontaneously developed invasive malignant lymphoma (48%, 19/40) and lung-metastasizing liver cancer (hepatocellular carcinoma) (35%, 14/40) that models human hepatocarcinogenesis, indicating the FEAT protein potently drives tumorigenesis in vivo. Gene expression profiling suggested that FEAT drives receptor tyrosine kinase and hedgehog signalling pathways. These findings demonstrate that integrated efforts to identify FEAT-like ubiquitous oncoproteins are useful and may provide promising approaches for cost-effective cancer screening and prevention.